NCT07455552Completed
Smartphone-based Telerehabilitation Versus Home-based Inspiratory Muscle Training After Lung Resection in High-risk Patients
Smartphone-based Telerehabilitation Versus Unsupervised Home-based Inspiratory Muscle Training After Lung Resection in High-risk Patients: a Pilot Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 24 Jun 2026
Brief summary (registry, in English)
The goal of this pilot clinical trial is to assess the feasibility of smartphone-based telerehabilitation for inspiratory muscle training (IMT) and to explore its preliminary effects on postoperative recovery in high-risk adult patients after lung resection. Eligible participants are adults aged 19 years or older who underwent lung resection and met at least one high-risk criterion: preoperative forced expiratory volume in 1 second (FEV1) or diffusing capacity of the lung for carbon monoxide (DLCO) of 70% predicted or less, or age 65 years or older. The main questions it aims to answer are: Is smartphone-based telerehabilitation for IMT feasible and safe in this patient population? Does smartphone-based telerehabilitation for IMT show preliminary effects on functional exercise capacity, as measured by the 6-minute walk test (6MWT)? Researchers will compare smartphone-based telerehabilitation IMT with unsupervised home-based IMT to see whether remote supervision provides additional benefit after lung resection. Participants will: be randomized to either smartphone-based telerehabilitation IMT or unsupervised home-based IMT perform IMT 5 days per week for 6 weeks, starting at 20% of postoperative maximal inspiratory pressure (MIP) with progression according to tolerance complete outcome assessments at postoperative weeks 2-4, 8-10, and 14-16, including the 6MWT, pulmonary function tests (FVC, FEV1, MIP, and peak expiratory flow), handgrip strength, body composition, patient-reported outcomes, and cardiopulmonary exercise testing at final follow-up
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 58 (actual)
- First submitted
- 9 Jul 2025
- Start date
- 13 Aug 2024
- Primary completion date
- 1 Feb 2026
- Lead sponsor
- Pusan National University Hospital
- Diseases
- Lung cancer
- NCT number
- NCT07455552
What you commit to
- Study type: Interventional
- Participants enrolled: 58
- From 13 Aug 2024 to the primary completion date, 1 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with limited mobility due to other conditions that could interfere with the exercise stress test or 6-minute walk test (e.g., osteoarthritis, spinal disorders, or cerebral infarction)
Other
- Pregnant women or other vulnerable populations considered inappropriate for study participation
- Patients with an implanted pacemaker or defibrillator that precluded bioelectrical impedance analysis
- Patients participating in other clinical studies that could affect exercise capacity
- Patients unable to independently use the messenger application (KakaoTalk) after standardized instruction
- Patients judged by the investigator to be unsuitable for participation
Who the study is looking for
- Adults aged 19 years or older
- Patients who underwent lung resection
- Patients who met at least one of the following high-risk criteria:
- preoperative FEV1 or DLCO ≤70% predicted
- age ≥65 years
- Patients who understood the study procedures and provided written informed consent
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PusanNUH Coordinator of this site? Confirm its status | Pusan | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.